AstraZeneca, the UK-based global pharmaceutical company, is withdrawing its diabetes treatment Forxiga (ingredient: dapagliflozin) from the Korean market, ten years since its approval in 2013 in Korea. Initially approved as SGLT-2 inhibitor-class diabetes treatment, Forxiga achieved success as its indications were expanded to include conditions like heart failure and kidney disease. Forxiga generated sales of 55 billion won in the previous year.

However, AstraZeneca has decided to withdraw Forxiga from the Korean market, giving up annual sales of 50 million won. This decision entails not only the supply halt, but also the withdrawal of approval and reimbursement. What factors have influenced As